Posted in | News | Nanobusiness

NanoViricides Completes Number of Financing Activities

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has completed a number of financing activities.

The Company has successfully raised more than $4.3M. This raise involved issuance of restricted shares and warrant conversions in private placements to certain accredited investors. The Company is filing a Form 8-K disclosure with the SEC summarizing these activities on October 5, 2009.

“With sufficient working capital to last us through December 31, 2010,” said Eugene Seymour, MD, MPH, CEO of the Company, “we are now ready to engage full steam with our high priority drug development activities.”

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, March 18). NanoViricides Completes Number of Financing Activities. AZoNano. Retrieved on April 17, 2024 from https://www.azonano.com/news.aspx?newsID=13964.

  • MLA

    NanoViricides, Inc. "NanoViricides Completes Number of Financing Activities". AZoNano. 17 April 2024. <https://www.azonano.com/news.aspx?newsID=13964>.

  • Chicago

    NanoViricides, Inc. "NanoViricides Completes Number of Financing Activities". AZoNano. https://www.azonano.com/news.aspx?newsID=13964. (accessed April 17, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides Completes Number of Financing Activities. AZoNano, viewed 17 April 2024, https://www.azonano.com/news.aspx?newsID=13964.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.